Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. - Wikidata - awgldk - TriplyDB

Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction.

Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction.

http://www.wikidata.org/entity/Q40579493

about

Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis Infliximab-Related Infusion Reactions: Systematic Review SAMP1/YitFc mouse strain: a spontaneous model of Crohn's disease-like ileitis.Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis.Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases.Current therapy of ulcerative colitis in children.Infliximab in the treatment of Crohn's disease.Polypharmacy and Crohn's disease.Managing complicated Crohn's disease in children and adolescents.Infliximab therapy for pediatric Crohn's disease.Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease Use of immunomodulators and biologic therapies in children with inflammatory bowel disease.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.Acute infusion reactions induced by monoclonal antibody therapy.Exploring the differential diagnosis of joint complaints in pediatric patients with inflammatory bowel disease.Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.Infliximab for the treatment of pediatric ulcerative colitis.Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.Premedication Use in Preventing Acute Infliximab Infusion Reactions in Patients with Inflammatory Bowel Disease: A Single Center Cohort Study.Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a Biologics in dermatology: adverse effects.Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience.Serum sickness-like reaction due to Infliximab reintroduction during pregnancy.Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients.Durability of infliximab in Crohn's disease: a single-center experience.Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.Clinical and radiologic analysis of on-demand use of etanercept for disease flares in patients with rheumatoid arthritis for 2 years: The RESUME study: A case-control study

P2860

Q24245033-F33A5DE0-CD40-4579-B0F0-A682954A2C97 Q27013835-0A866961-9399-429B-A70F-AF342FADCFFF Q30423660-1C8E9667-D546-4A12-90EC-3E16FE9155F5 Q34654104-54D2F512-009B-4851-9151-4F7D69C035CC Q35030557-A55DD866-D8CD-4203-8E49-7A3CF778C78D Q35116177-B0A340BE-9D08-4833-BFBD-A9010343CBFC Q35609674-CFF4E576-C2A3-4C17-93F5-CAAF75DA070A Q35919228-72F40753-0A85-40FA-ABC8-A50285062C1D Q36120936-849B213F-642F-409D-8763-1050F92ACD64 Q36331225-F4247A40-BD42-4008-AD1A-D3528B377ED1 Q37012073-0D05A3BE-CEA9-4C49-9B7A-911D5FD9E4EA Q37033874-60753F75-2674-4DD1-B511-D8C19A890081 Q37609746-8633E687-B4AD-4F48-90A3-38260F1C73E4 Q37769253-D76FBEB5-E4D3-4434-A34B-061BC2ABB952 Q37814549-1E0AA691-442A-4AB1-9F05-C91F7818A9AF Q37821495-FF615575-A304-4D76-9BE0-866FE08BDCEF Q37836510-BACB3052-B357-43B0-8233-90F9B18A2715 Q37936394-955AF367-777F-475C-9C93-A65EBA2E72BD Q38067127-3F04D686-EB9E-4C3A-9F42-25920DF80687 Q38202541-1BD5F346-041F-4E0F-B08C-C5CEA48994FB Q38637766-C5EC0383-9662-4C75-9490-44C8ECD16F5B Q38673082-F68B56A9-5596-42AC-BE8A-65C05EE9A871 Q39113455-3C932214-CFB3-4719-80CD-5A5889A753AA Q41120913-C4366EFC-BEC4-4D9D-A048-FE6F086F079D Q46234832-8F9FFCC6-E8B9-402C-BBE3-8BACD9A589DF Q46469250-9DC4180C-84E2-46F4-B5D5-0F58DF71D042 Q46545377-420E133E-AA63-4C46-B52D-5B000EDE5AF4 Q46935733-3179BB92-2753-4E5D-9020-B66A0DEB5A03 Q47159585-36679CBF-E2AD-45EB-9A72-FBB89CB77E8E Q47744808-069738B0-DEF5-4DB0-86C6-9905F436B9E4 Q51036254-A06A7A8F-7278-4192-87AF-4119463EDFF9 Q58703890-E0299C59-EB0C-4D32-917E-D9D6A3143E63

P2860

Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction.

http://www.wikidata.org/entity/Q40579493

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Infliximab retreatment in adul ...... ayed severe systemic reaction.

@en

type

label

Infliximab retreatment in adul ...... ayed severe systemic reaction.

@en

prefLabel

Infliximab retreatment in adul ...... ayed severe systemic reaction.

@en

P1433

Q40579493-085DB839-1237-43DB-B28A-84E8C7E0B056

P1476

Q40579493-3AE56E83-8F29-4849-88AA-C48A5822731E

P2093

Q40579493-24E94ACB-06F0-4ECB-8F29-2111720D7659

Q40579493-5464B932-984B-47C3-9C66-DFAE24ABA7BF

Q40579493-71AAD7E1-0E65-4933-9A00-6E02D03CEF01

Q40579493-734780DD-7F41-4697-8BAE-1C1B9D6ECEE4

Q40579493-A38280A7-18D6-4FBE-934C-E8065DAE47ED

Q40579493-A484582E-9BCE-471B-A27E-F5507FC6A576

Q40579493-AABD617F-6AEA-4346-8B2F-7FEC0A034266

Q40579493-C05F4C51-2462-416F-8B3C-CA58233A52B6

Q40579493-C8214DF9-07CC-454B-AEF3-6FBEE1894E0F

Q40579493-E61BEC82-B752-4C28-B1BE-D6C0A1BEC22C

P2860

Q40579493-14416039-E5EE-4ED7-ADEE-59A0EA2C6BCE

Q40579493-8F495DE6-6BEE-4FC4-84AB-08DC6619105A

Q40579493-B89BFDE7-6EE1-42BF-B988-D0F6DF833B33

P304

Q40579493-8C8B66B6-B071-46E1-A87A-D4A49B1673A1

P31

Q40579493-801CEC2B-244C-479F-819F-59B24E5DC162

P356

Q40579493-10CF9C9A-2062-412D-B081-F8C06D785C95

P407

Q40579493-42F96C9A-AB6F-4F92-B9B1-33B3CA83CABF

P433

Q40579493-B20D86E0-2992-4C61-B66E-6F8F3A50FB1C

P478

Q40579493-3983FA2D-82C1-4388-9AB8-5CA0309D8EA0

P577

Q40579493-F46F53DA-BED2-423C-87A3-C0C7D4667249

P698

Q40579493-BDFB52C6-4C23-42BF-8003-EFB22D52A932

P356

J.1572-0241.2002.05784.X

P1433

The American Journal of Gastroenterology

P1476

Infliximab retreatment in adul ...... ayed severe systemic reaction.

@en

P2093

Alfonso Martinez

http://www.w3.org/2001/XMLSchema#string

David G Binion

http://www.w3.org/2001/XMLSchema#string

Devang Prajapati

http://www.w3.org/2001/XMLSchema#string

Jeanne Emmons

http://www.w3.org/2001/XMLSchema#string

Joseph P Kim

http://www.w3.org/2001/XMLSchema#string

Kevin J Kelly

http://www.w3.org/2001/XMLSchema#string

Kia Saeian

http://www.w3.org/2001/XMLSchema#string

Michael B Levy

http://www.w3.org/2001/XMLSchema#string

Sotirios Vasilopoulos

http://www.w3.org/2001/XMLSchema#string

Subra Kugathasan

http://www.w3.org/2001/XMLSchema#string

P2860

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Infliximab for the treatment of fistulas in patients with Crohn's disease.

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

P304

1408-1414

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1572-0241.2002.05784.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2002-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12094858

http://www.w3.org/2001/XMLSchema#string